Aug 2026· Frontiers in Genetics· Vol 17· 0 citations· 102 references
Medicine
TL;DR
These findings provide a hypothesis-generating reframing of the traditional comorbidity model, suggesting that divergent molecular programs may converge on shared pathways and offer a preliminary foundation for exploring therapeutic strategies at the mood–metabolism interface.
Abstract
Introduction Major depressive disorder (MDD) and obesity are intersecting global crises. Despite observational links, a clinical paradox persists: antidepressants often improve metabolic status, while weight loss rarely alleviates core depressive symptoms. This prompts closer examination of whether the depression–obesity relationship reflects asymmetric genetic architecture, shared liability, or statistical constraints that obscure definitive conclusions. Methods We developed an integrative multi-omics framework leveraging large-scale population data from the National Health and Nutrition Examination Survey (NHANES) and East Asian genetic data. Epidemiological regression was applied to NHANES to characterize real-world phenotypic cross-talk. We utilized bidirectional Mendelian randomization (MR) to explore the direction of association, targeted summary-data-based MR (SMR) with heterogeneity in dependent instruments (HEIDI) testing to prioritize candidate functional genes, and single-cell RNA sequencing (scRNA-seq) of regulatory T cells (Tregs). In silico cell composition adjustment and virtual knockout (VKO) simulations were implemented to distinguish intrinsic cellular remodeling from compositional shifts and to infer convergent downstream programs. Results Bidirectional MR yielded a nominally significant association from MDD to obesity risk (β = 0.0458, P = 0.0209), whereas the reverse path was inconclusive due to low statistical power (<10%), precluding definitive conclusions about directionality. SMR/HEIDI identified multiple FDR-significant obesity-associated genes, including NT5C2, ACYP2, and TMEM180, whereas on the depression side only ACAT1 reached nominal significance, positioning it as a borderline hypothesis-generating candidate. Cell composition adjustment suggested that transcriptional signals reflected intrinsic remodeling, preserving up to 98% of effect sizes for top candidates. At the molecular level, the conditions diverged: obesity risk was dominated by immune-compartment inflammation and post-transcriptional splicing dysregulation, whereas MDD risk was characterized by ribosomal translation perturbations. Strikingly, VKO simulations revealed convergence on a shared downstream program anchored in cytoskeletal reorganization and E2F-target modulation. Exploratory druggability screening nominated FDFT1 (with a phase 3 inhibitor) and ADORA2A as potential repurposing candidates requiring experimental validation. Conclusion Our findings provide a hypothesis-generating reframing of the traditional comorbidity model, suggesting that divergent molecular programs may converge on shared pathways. Although the full extent of bidirectional genetic relationships remains unconfirmed, these findings offer a preliminary foundation for exploring therapeutic strategies at the mood–metabolism interface.
Background/Objectives: Substance use behaviors share a complex, overlapping polygenic architecture, yet translating genome-wide association study (GWAS) findings into actionable biological mechanisms remains challenging. This study aimed to characterize the genetic architecture of five substance use traits (alcohol consumption, alcohol dependence, nicotine use, illicit drug use, and behavioral disinhibition) and identify shared and distinct gene expression signatures within the neural circuits governing addiction. Methods: We reanalyzed 7188 individuals from the Minnesota Center for Twin and Family Research (MCTFR) cohort utilizing longitudinal composite phenotypes spanning five substance-use domains and general behavioral disinhibition. Post-QC, 6874 individuals were retained for downstream analysis. Following genomic imputation and linear mixed model GWAS (GEMMA), we utilized the SNipar framework to partition polygenic risk scores (PRS) into direct and indirect genetic effects, investigating intergenerational shifts in genetic penetrance and effects of assortative mating. Finally, we integrated our summary statistics with brain tissue reference panels to perform a transcriptome-wide association study (TWAS) modeling genetically regulated gene expression within neural circuits relevant to addiction. Results: Partitioning of polygenic risk revealed that while surface-level parental DNA correlations were modest (r = 0.08), underlying latent genetic correlations approached unity (Rδ ≈ 0.99), indicating that addiction risk clustering in families is driven by intense assortive mating and concentrated biological inheritance. Multi-phenotype TWAS identified several significant gene–phenotype associations—notably ADAM32 and SLC9A3, which demonstrated pleiotropic effects across multiple substance use categories. Crucially, these significant TWAS signals were enriched in striatal structures (caudate, putamen, substantia nigra) and frontal cortical regions. Conclusions: Our findings support a model of shared genetic liability across diverse substance use behaviors, mediated by specific gene expression patterns in the mesolimbic dopamine system and frontal cortex. By integrating multi-phenotype GWAS and TWAS, this study highlights pleiotropic candidate genes and provides critical insights into the tissue-specific neurobiological pathways underlying addiction vulnerability.
Jiahua Zhou, An-Phuc Ta, Catherine Yang et al.· Biomedicines· 0 citations
Background: The directional relationship between epigenetic age acceleration (EAA) and musculoskeletal disease remains unresolved. This study integrated bidirectional Mendelian randomization (MR) with multi-layer genomic evidence to evaluate directionality, shared genetic architecture, and robustness to instrument definition. Methods: Four EAA clocks (IEAA, PhenoAA, HannumAA, and GrimAA) and ten musculoskeletal phenotypes were analyzed in a 10 × 4 bidirectional two-sample MR design. EAA instruments underwent GRCh37 functional annotation, genome-wide-significant external-association screening for the index variants and European linkage-disequilibrium proxies, pair-specific Steiger filtering, and conservative Set A/B/C sensitivity analyses. The juvenile-arthritis reverse models underwent instrument-flow reconstruction, strength assessment, liability-scale directionality testing, and minimum-detectable-effect analysis. Additional analyses comprised LD score regression (LDSC), PLACO+ cross-trait locus mapping, Bayesian colocalization, multivariable MR (MVMR) with exact-SNP matched univariable comparators, and integrated evidence synthesis. Results: Forward MR yielded two nominal HannumAA associations. The inverse HannumAA–spondyloarthritis estimate remained directionally consistent across the original, Steiger-filtered, and conservative external-association-filtered sets, whereas the HannumAA–pain-in-thoracic-spine estimate lost nominal significance in the conservative set; no forward result survived correction across 40 tests. GrimAA forward estimates were sensitive to use of the fallback instrument threshold. Reverse MR identified ten nominal associations. For juvenile arthritis, three harmonized instruments had F statistics of 51.25–102.35; liability-scale Steiger comparisons supported the tested direction under all 16 outcome-by-prevalence combinations, although the 788-case discovery GWAS and possible winner’s curse remained important limitations. LDSC identified FDR-significant positive genetic correlations of GrimAA with hip osteoarthritis (r_g = 0.267, p = 8.49 × 10−5, q = 0.0019) and knee osteoarthritis (r_g = 0.269, p = 9.52 × 10−5, q = 0.0019). PLACO+ identified 738 genome-wide-significant cross-trait variants and 65 independent loci; six of 37 evaluable loci showed strong colocalization. Of 96 MVMR models, 43 had primary-exposure conditional F ≥ 10, and 32 also had candidate-trait conditional F ≥ 10. After exact-SNP matching, the 43 primary-strength models were operationally classified as 35 partially attenuated and eight independent-signal models, with no fully attenuated model; no adjusted association survived multiplicity correction. Conclusions: The results support a prioritized genomic map with substantial instrument- and model-specific uncertainty. Disease-to-clock signals were richer than clock-to-disease signals, GrimAA shared polygenic architecture with osteoarthritis, and selected loci showed strong shared-variant evidence, while the MR and MVMR findings remained unsuitable for definitive causal or mediation claims.
Major depressive disorder (MDD) has a widespread heterogeneity as per the psychiatric nosology, and traditional symptom-based diagnosis frameworks do not offer many clues regarding tailored therapy techniques. The recent development of multi-omics and data-driven solutions has now provided evidence for pathophysiologically different subtypes of MDD, moving the field toward precision psychiatry. The systematic review aggregates multimodal studies that combing neuroimaging, genomics, transcriptomics, epigenomics, metabolomics, and proteomics to define MDD subtypes. There are two to four candidate clusters that have been formed across these heterogeneous modalities, and each has a neurobiological and clinical profile. Cognitive subtypes are characterized by executive failure and loss of prefrontal and temporal gray matter. Neuroimaging-derived subtypes show specific patterns of functional connectivity that may predict response to selective serotonin reuptake inhibitors (SSRIs) or repetitive transcranial magnetic stimulation (rTMS) in preliminary studies. There are immune-metabolic subtypes characterized by increased inflammatory cytokines and dysregulation of metabolic pathways. Molecular subtypes appear to be differentiated by cellular mechanisms such as mitophagy and pyroptosis. Taken together, these results indicate that multi-omics integration, in addition to explaining the molecular architecture of MDD, also characterizes patient subgroups with pathophysiological mechanisms, dimensions of symptoms, and disease treatment. The growing body of literature demonstrates that there is a shift in psychiatry toward a more mechanistic approach and that biomarker-based diagnostics and personalized treatment regimens are urgently needed to improve clinical outcomes in depressive diseases.
E. Amjad, B. Sokouti· OBM Neurobiology· 0 citations
It is indicated that the causal effect of BMI on depression detected in typical non-clustered Mendelian randomization is driven to an extent by appetite, with no or inconsistent evidence for effects on core psychological symptoms such as anhedonia and depressed mood.
Stephanie Sheir, Giulia G. Piazza, N. Davies et al.· Molecular Psychiatry· 0 citations
Background Irritable bowel syndrome (IBS) is a complex disorder of gut-brain interaction, with heterogeneous symptoms, no available biomarkers and limited pathogenetic insight. Objective To identify genetic risk factors and actionable mechanisms for future clinical translation in IBS. Design We conducted a genome-wide association study (GWAS) meta-analysis of IBS in 2 775 539 individuals from 22 biobanks. IBS genetics was studied across multiple ancestries, different case definitions and symptom-related subtypes. Heritability and genetic correlations with other traits were estimated, and Mendelian randomisation was used to test causal relationships. GWAS data were functionally annotated and fine-mapped to prioritise tissues, cell types, pathways, candidate genes, specific mechanisms and druggable targets. Results Significant heritability was only detected in individuals of European ancestry, with near-identical genetic architecture across case definitions. Genetic correlations with GI, psychiatric and cardiometabolic traits were observed, including causal relationships with triglyceride (TG) levels. Functional annotation of IBS risk loci highlighted cell types and pathways relevant to brain, enteric neuro-glial and cardiometabolic domains, as well as actionable targets like GCKR, a regulator of TG metabolism. Druggability analyses converged on cardiometabolic mechanisms, including TG modulation. IBS polygenic risk scores were derived and showed a significant association with case status in an independent case-control dataset, supporting further evaluation in external population-based and clinically ascertained cohorts. Conclusions This study provides the most comprehensive assessment of IBS genetics to date, demonstrating reproducible polygenic inheritance. We link IBS risk to convergent neurogastrointestinal and novel cardiometabolic mechanisms, highlight specific biological pathways and actionable mechanisms and outline translational opportunities emerging from integrated computational analyses.
Biagio Di Lorenzo, L. Camargo Tavares, Cristian Díaz-Muñoz et al.· Gut· 0 citations